RVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
16 Jun 2022
RVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
BRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the Company’s Annual General Meeting.
At the Annual General Meeting of the Company held on June 16, 2022 (the AGM), the resolution placed before the meeting in respect of the approval of the waiver under Rule 9 of the Irish Takeover Rules (the Rules) was duly passed by independent shareholders of the Company on a poll. The result of the poll was 28,894,940 votes for; and 1,340,770 votes against.
Accordingly, the aggregate percentage shareholding in the capital of the Company held by the parties specified in the table below (and persons deemed to be acting in concert with them under the Rules) (together, the Affected Parties) may proportionally increase up to the maximum percentage specified below in the event of the issue by the Company of up to 17,000,000 new ordinary shares of US$0.01 each in the capital of the Company. In such circumstances, the Affected Parties will not incur an obligation under Rule 9 of the Rules to make a general offer to the Company's other shareholders.
Current Shareholding
(Number)
Current Shareholding
(%)Potential Shareholding
following Share Issues
(%)Avista Healthcare Partners, L.P., and Orbit Co-Invest III LLC
16,763,859 ordinary shares20.07%24.64%Altchem Limited and Orbit Co-Invest A-1 LLC
23,667,540 ordinary shares28.34%31.51%Management Individuals (as defined in the Proxy Statement)2,115,895 ordinary shares2.53%3.1% The full text of the resolution (being Proposal 3) is set out in the Proxy Statement in respect of the AGM which is available at https://www.rvlpharma.com/.
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.
Investor and Media Relations for RVL Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.